RecruitingNCT04113993
Study of bazedoxifene added to usual care for women with schizophrenia
About this title
Read the official source — NCT04113993Medication studyAges 18–65Australia
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- MelbourneSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 7, 2019
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 160
- Sponsor
- The Alfred
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Australia
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04113993
- Official title
Show the full official title
Bazedoxifene - A New Selective Estrogen Receptor Modulator Treatment for Women With Schizophrenia: a Double-blind, Randomized, Placebo Controlled Trial
Recruitment & locations
RecruitingMelbourne
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is The Alfred.
Does this study involve medication?
Yes. The study involves medication, including Bazedoxifene Acetate and Placebo.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
